<DOC>
	<DOCNO>NCT02412319</DOCNO>
	<brief_summary>Asses efficacy safety Anti hepatitis B placenta transfer factor injection treatment HBeAg positive chronic hepatitis B .</brief_summary>
	<brief_title>The Clinical Trial Anti Hepatitis B Placenta Transfer Factor Injection</brief_title>
	<detailed_description>This study use entecavir tablet basic therapy , randomize , double-blind , placebo-controlled multi center study , include screen period ( -4 week ) , baseline treatment period ( 96 week ) . The treatment period first 48 week , use entecavir tablet basic treatment , placebo-controlled trial ; second 48 week , take entecavir tablet alone , continue observation experiment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1. aged 1865 , sex limit ; 2. patient HBeAg positive chronic hepatitis B : Screening HBsAg positive 6 month ; screen HBeAg positive ; screen serum HBV DNA≥1.0×105U/ml； 3 . 2 * ULN ( 2 time upper limit normal value ) &lt; ALT &lt; 10 * ULN ( 10 time upper limit normal value ) ; ; 4. total bilirubin &lt; 51μmol/L ; 5. hepatitis B virus resistance gene sequence negative ; 6. agree process study , participate clinical study anti HBV therapy ; 7. beginning study , understand sign inform consent form approve ethic committee , cooperate conduct clinical research accord requirement study . 1. follow evidence prompt suspect hepatocellular carcinoma : B ultrasound image examination discover occupy lesion ; B ultrasound normal serum alpha fetoprotein ( AFP ) level continuous increase trend ; AFP &gt; 100ng/ml , review , still . 2. liver disease acute exacerbation cause transient liver function decompensation disease baseline clinical performance decompensated liver disease ; 3. serum creatinine ≥1.5mg/dl ( ≥130μmol/l ) ; 4. serum amylase &gt; 2 time normal reference upper limit value ; 5. hemoglobin ( male &lt; 100g/L , female &lt; 90g/L ) , white blood cell &lt; 3.5* 109/L , platelet &lt; 60 * 109/L ; 6. combined infection HCV ( anti HCV positive ) , HIV , anti HAV IgM positive , anti HDV IgM positive , anti HEV IgM positive , anti EBV IgM positive , anti CMV IgM positive , autoimmune hepatitis ( titer anti nuclear antibody &gt; 1:160 ) activite liver disease cause know unknown reason ; 7. investigator consider may interfere treatment , evaluation compliance subject , include uncontrolled clinical significance kidney , heart , lung , blood vessel , neurogenic , digestive system , metabolic disease ( diabetes , hyperthyroidism , adrenal disease ) , immune function disorder tumor ; 8. subject history alcoholism drug abuse , investigator consider subject comply protocol affect result analysis ; 9. pregnancy , lactation female subject plan conceive companion male subject plan conceive study 10 . 6 month study medication use immunosuppressant , immunomodulators ( thymosin alpha ) , cytotoxic drug ; 11 . 6 month study medication use anti HBV drug therapy ( interferon , Lamivudine , Adefovir , Entecavir Telbivudine , Tenofovir , etc ) ; 12. plan liver transplantation ; 13. receive study drug treatment within 3 month prior screen ; 14. drug allergy history allergic Nucleoside Nucleotide drug ; 15. subject non compliance protocol subject exist situation investigator consider suitable participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HBeAg positive chronic hepatitis B</keyword>
	<keyword>HBeAg serum conversion rate</keyword>
	<keyword>HBeAg serum disappearance rate</keyword>
	<keyword>HBeAg HBsAg titer</keyword>
</DOC>